Cyclerion Therapeutics Statistics Share Statistics Cyclerion Therapeutics has 3.34M
shares outstanding. The number of shares has increased by 18.45%
in one year.
Shares Outstanding 3.34M Shares Change (YoY) 18.45% Shares Change (QoQ) 18.45% Owned by Institutions (%) 14.61% Shares Floating 2.02M Failed to Deliver (FTD) Shares 111 FTD / Avg. Volume 0.31%
Short Selling Information The latest short interest is 17.18K, so 0.56% of the outstanding
shares have been sold short.
Short Interest 17.18K Short % of Shares Out 0.56% Short % of Float 0.7% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -2.65 and the forward
PE ratio is -0.11.
Cyclerion Therapeutics's PEG ratio is
0.03.
PE Ratio -2.65 Forward PE -0.11 PS Ratio 4.05 Forward PS 0.1 PB Ratio 0.92 P/FCF Ratio -1.87 PEG Ratio 0.03
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Cyclerion Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 5.83,
with a Debt / Equity ratio of 0.
Current Ratio 5.83 Quick Ratio 5.83 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $2M Profits Per Employee $-3.06M Employee Count 1 Asset Turnover 0.21 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -29% in the
last 52 weeks. The beta is 1.68, so Cyclerion Therapeutics's
price volatility has been higher than the market average.
Beta 1.68 52-Week Price Change -29% 50-Day Moving Average 3.02 200-Day Moving Average 2.96 Relative Strength Index (RSI) 34.47 Average Volume (20 Days) 35,820
Income Statement In the last 12 months, Cyclerion Therapeutics had revenue of 2M
and earned -3.06M
in profits. Earnings per share was -1.21.
Revenue 2M Gross Profit 2M Operating Income -3.63M Net Income -3.06M EBITDA -3.63M EBIT -3.63M Earnings Per Share (EPS) -1.21
Full Income Statement Balance Sheet The company has 3.23M in cash and 0 in
debt, giving a net cash position of 3.23M.
Cash & Cash Equivalents 3.23M Total Debt n/a Net Cash n/a Retained Earnings -267.49M Total Assets 9.37M Working Capital 3.22M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -4.33M
and capital expenditures 0, giving a free cash flow of -4.33M.
Operating Cash Flow -4.33M Capital Expenditures n/a Free Cash Flow -4.33M FCF Per Share -1.72
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -181.4% and -152.85%.
Gross Margin 100% Operating Margin -181.4% Pretax Margin -152.85% Profit Margin -152.85% EBITDA Margin -181.4% EBIT Margin -181.4% FCF Margin -216.65%
Dividends & Yields CYCN does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for CYCN.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on May 16, 2023. It was a
backward
split with a ratio of 1:20.
Last Split Date May 16, 2023 Split Type backward Split Ratio 1:20
Scores Altman Z-Score -35.01 Piotroski F-Score 2
